Abciximab
Etoricoxib may increase the anticoagulant activities of Abciximab.
Abiraterone
The serum concentration of Etoricoxib can be increased when it is combined with Abiraterone.
Acebutolol
Etoricoxib may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Etoricoxib.
Acemetacin
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Acemetacin.
Acenocoumarol
Etoricoxib may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib.
Aclarubicin
Etoricoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Etoricoxib.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.
Aliskiren
Etoricoxib may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Etoricoxib.
Alprenolol
Etoricoxib may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Etoricoxib.
Amcinonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Amcinonide.
Amikacin
Etoricoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Etoricoxib may decrease the antihypertensive activities of Amiloride.
Amiodarone
The metabolism of Etoricoxib can be decreased when combined with Amiodarone.
Ancrod
Etoricoxib may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Androstenedione.
Anhydrous Tacrolimus
Etoricoxib may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.
Antithrombin III
Etoricoxib may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Etoricoxib may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Etoricoxib can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Etoricoxib.
Apixaban
Etoricoxib may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Etoricoxib.
Aprepitant
The serum concentration of Etoricoxib can be increased when it is combined with Aprepitant.
Arbekacin
Etoricoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Etoricoxib may increase the anticoagulant activities of Ardeparin.
Argatroban
Etoricoxib may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Etoricoxib may increase the anticoagulant activities of Argatroban.
Artemether
The metabolism of Etoricoxib can be decreased when combined with Artemether.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib.
Atazanavir
The metabolism of Etoricoxib can be decreased when combined with Atazanavir.
Atenolol
Etoricoxib may decrease the antihypertensive activities of Atenolol.
Atomoxetine
The metabolism of Etoricoxib can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Atorvastatin.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Etoricoxib.
azficel-T
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.
Azithromycin
The metabolism of Etoricoxib can be decreased when combined with Azithromycin.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Etoricoxib.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Etoricoxib.
Becaplermin
Etoricoxib may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Etoricoxib.
Betamethasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Betamethasone.
Betaxolol
The metabolism of Etoricoxib can be decreased when combined with Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Etoricoxib.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etoricoxib.
Bisoprolol
Etoricoxib may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Etoricoxib may increase the anticoagulant activities of Bivalirudin.
Boceprevir
The metabolism of Etoricoxib can be decreased when combined with Boceprevir.
Bopindolol
Etoricoxib may decrease the antihypertensive activities of Bopindolol.
Bortezomib
The metabolism of Etoricoxib can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Etoricoxib can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Etoricoxib.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Etoricoxib.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Etoricoxib.
Budesonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Etoricoxib.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Etoricoxib.
Bupranolol
Etoricoxib may decrease the antihypertensive activities of Bupranolol.
Bupropion
The metabolism of Etoricoxib can be decreased when combined with Bupropion.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Etoricoxib.
Caffeine
The metabolism of Etoricoxib can be decreased when combined with Caffeine.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etoricoxib.
Capecitabine
The metabolism of Etoricoxib can be decreased when combined with Capecitabine.
Captopril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Captopril.
Carbamazepine
The metabolism of Etoricoxib can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etoricoxib.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etoricoxib.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Etoricoxib.
Carteolol
Etoricoxib may decrease the antihypertensive activities of Carteolol.
Carvedilol
Etoricoxib may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.
Celiprolol
Etoricoxib may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Etoricoxib can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Etoricoxib.
Certoparin
Etoricoxib may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Etoricoxib.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.
Chlorotrianisene
Etoricoxib may increase the thrombogenic activities of Chlorotrianisene.
Chlorpromazine
The metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etoricoxib.
Cholecalciferol
The metabolism of Etoricoxib can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etoricoxib.
Ciclesonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Cilazapril.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Etoricoxib.
Cimetidine
The metabolism of Etoricoxib can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Etoricoxib can be decreased when combined with Cinacalcet.
Cinoxacin
Etoricoxib may increase the neuroexcitatory activities of Cinoxacin.
Citalopram
Citalopram may increase the antiplatelet activities of Etoricoxib.
Citric Acid
Etoricoxib may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Etoricoxib may increase the anticoagulant activities of Citric Acid.
Clarithromycin
The metabolism of Etoricoxib can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Etoricoxib can be decreased when combined with Clemastine.
Clobazam
The metabolism of Etoricoxib can be decreased when combined with Clobazam.
Clobetasol
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Clodronic Acid.
Clomipramine
The metabolism of Etoricoxib can be decreased when combined with Clomipramine.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Etoricoxib.
Clotrimazole
The metabolism of Etoricoxib can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Etoricoxib can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Etoricoxib can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Etoricoxib can be decreased when combined with Cocaine.
Colesevelam
Colesevelam can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Etoricoxib.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Cortisone acetate.
Crisaborole
The metabolism of Etoricoxib can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Etoricoxib can be decreased when combined with Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Etoricoxib.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etoricoxib.
Cyclosporine
Etoricoxib may increase the nephrotoxic activities of Cyclosporine.
Cyproterone Acetate
The serum concentration of Etoricoxib can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
Etoricoxib may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.
Dalteparin
Etoricoxib may increase the anticoagulant activities of Dalteparin.
Danaparoid
Etoricoxib may increase the anticoagulant activities of Danaparoid.
Darifenacin
The metabolism of Etoricoxib can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Etoricoxib can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.
Daunorubicin
Etoricoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox
The serum concentration of Etoricoxib can be decreased when it is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Deflazacort.
Delavirdine
The metabolism of Etoricoxib can be decreased when combined with Delavirdine.
Desipramine
The metabolism of Etoricoxib can be decreased when combined with Desipramine.
Desirudin
Etoricoxib may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Etoricoxib.
Dexamethasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etoricoxib.
Dextran
Etoricoxib may increase the anticoagulant activities of Dextran.
Dextran 40
Etoricoxib may increase the anticoagulant activities of Dextran 40.
Dextran 70
Etoricoxib may increase the anticoagulant activities of Dextran 70.
Dextran 75
Etoricoxib may increase the anticoagulant activities of Dextran 75.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Etoricoxib.
Dicumarol
Etoricoxib may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Etoricoxib may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Etoricoxib may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Etoricoxib.
Difluprednate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Etoricoxib.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Etoricoxib.
Dihydrostreptomycin
Etoricoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Diltiazem
The metabolism of Etoricoxib can be decreased when combined with Diltiazem.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Etoricoxib.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etoricoxib.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etoricoxib.
Diphenhydramine
The metabolism of Etoricoxib can be decreased when combined with Diphenhydramine.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Etoricoxib.
Dothiepin
The metabolism of Etoricoxib can be decreased when combined with Dosulepin.
Doxorubicin
Etoricoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxorubicin Hydrochloride
Etoricoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxycycline
The metabolism of Etoricoxib can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Etoricoxib can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Etoricoxib can be decreased when combined with Dronedarone.
Drospirenone
Etoricoxib may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Etoricoxib.
Duloxetine
Duloxetine may increase the antiplatelet activities of Etoricoxib.
Edetic Acid
Etoricoxib may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Etoricoxib may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Etoricoxib can be decreased when combined with Efavirenz.
Eliglustat
The metabolism of Etoricoxib can be decreased when combined with Eliglustat.
Enalapril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalaprilat.
Enoxacin
Etoricoxib may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Etoricoxib may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Etoricoxib may increase the anticoagulant activities of Enoxaparin.
Enzalutamide
The serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.
Epirubicin
Etoricoxib may decrease the excretion rate of Epirubicin which could result in a higher serum level.
Eplerenone
Etoricoxib may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.
Equol, (-)-
Etoricoxib may increase the thrombogenic activities of Equol.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Etoricoxib.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Etoricoxib.
Erythromycin
The metabolism of Etoricoxib can be decreased when combined with Erythromycin.
Escitalopram
Escitalopram may increase the antiplatelet activities of Etoricoxib.
Esmolol
Etoricoxib may decrease the antihypertensive activities of Esmolol.
Estradiol
Etoricoxib may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Etoricoxib may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Etoricoxib may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Etoricoxib may increase the thrombogenic activities of Estradiol valerate.
Estriol
Etoricoxib may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Etoricoxib may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Etoricoxib may increase the thrombogenic activities of Estrogens, esterified.
Estrone
Etoricoxib may increase the thrombogenic activities of Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etoricoxib.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etoricoxib.
Ethinyl Estradiol
Etoricoxib may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Etoricoxib may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Etoricoxib.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Etoricoxib.
Etravirine
The metabolism of Etoricoxib can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Etoricoxib.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Etoricoxib.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Etoricoxib.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Etoricoxib.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Etoricoxib.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.
Fleroxacin
Etoricoxib may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Etoricoxib.
Floxuridine
The metabolism of Etoricoxib can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Etoricoxib can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fludrocortisone.
Fluindione
Etoricoxib may increase the anticoagulant activities of Fluindione.
Flumequine
Etoricoxib may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Etoricoxib.
Fluorouracil
The metabolism of Etoricoxib can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Etoricoxib can be decreased when combined with Fluoxetine.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etoricoxib.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone propionate.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Etoricoxib.
Fluvoxamine
The metabolism of Etoricoxib can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Etoricoxib.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Etoricoxib.
Fondaparinux
Etoricoxib may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Etoricoxib may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Formestane.
Fosamprenavir
The metabolism of Etoricoxib can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Etoricoxib can be increased when it is combined with Fosaprepitant.
Fosinopril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Fosinopril.
Fosphenytoin
The metabolism of Etoricoxib can be increased when combined with Fosphenytoin.
Framycetin
Etoricoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Etoricoxib.
Fusidate
The serum concentration of Etoricoxib can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Etoricoxib can be increased when it is combined with Fusidic Acid.
Gatifloxacin
Etoricoxib may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Etoricoxib may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Etoricoxib.
Gemfibrozil
The metabolism of Etoricoxib can be decreased when combined with Gemfibrozil.
Gemifloxacin
Etoricoxib may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Etoricoxib may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Etoricoxib may increase the thrombogenic activities of Genistein.
Gentamicin
Etoricoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Grepafloxacin
Etoricoxib may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.
Heparin
Etoricoxib may increase the anticoagulant activities of Heparin.
Hydralazine
Etoricoxib may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.
Hydrocortisone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etoricoxib.
Hypoxis hemerocallidea root extract
The serum concentration of Etoricoxib can be decreased when it is combined with St. John's Wort.
Ibandronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Etoricoxib.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Etoricoxib.
Idarubicin
Etoricoxib may decrease the excretion rate of Idarubicin which could result in a higher serum level.
Idelalisib
The metabolism of Etoricoxib can be decreased when combined with Idelalisib.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.
Imatinib
The metabolism of Etoricoxib can be decreased when combined with Imatinib.
Imidapril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Imidapril.
Imipramine
The metabolism of Etoricoxib can be decreased when combined with Imipramine.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.
Indinavir
The metabolism of Etoricoxib can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Etoricoxib can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Etoricoxib.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.
Irbesartan
The metabolism of Etoricoxib can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Etoricoxib can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Etoricoxib can be decreased when combined with Isavuconazonium.
Isoniazid
The metabolism of Etoricoxib can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Etoricoxib can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Etoricoxib can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Etoricoxib can be increased when it is combined with Ivacaftor.
Kanamycin
Etoricoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Etoricoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Etoricoxib.
Ketoconazole
The metabolism of Etoricoxib can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Etoricoxib.
Labetalol
Etoricoxib may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Etoricoxib.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Etoricoxib.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Etoricoxib.
Lepirudin
Etoricoxib may increase the anticoagulant activities of Lepirudin.
Levobunolol
Etoricoxib may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Etoricoxib may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Etoricoxib may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Etoricoxib.
Lidocaine
The metabolism of Etoricoxib can be decreased when combined with Lidocaine.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etoricoxib.
Lisinopril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Etoricoxib.
Lithium
The serum concentration of Lithium can be increased when it is combined with Etoricoxib.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Etoricoxib.
Lopinavir
The metabolism of Etoricoxib can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Etoricoxib can be decreased when combined with Lorcaserin.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Etoricoxib.
Losartan
The metabolism of Etoricoxib can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Loteprednol.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Etoricoxib.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Etoricoxib.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etoricoxib.
Luliconazole
The serum concentration of Etoricoxib can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Etoricoxib can be decreased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Etoricoxib can be decreased when combined with Lumefantrine.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.
Manidipine
The metabolism of Etoricoxib can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Etoricoxib.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.
Medronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etoricoxib.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Etoricoxib.
Mestranol
Etoricoxib may increase the thrombogenic activities of Mestranol.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Etoricoxib.
Methadone
The metabolism of Etoricoxib can be decreased when combined with Methadone.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Etoricoxib.
Methotrimeprazine
The metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Etoricoxib.
Methylprednisolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Methylprednisolone.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Etoricoxib.
Metipranolol
Etoricoxib may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Etoricoxib.
Metrizamide
Etoricoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.
Mexiletine
The metabolism of Etoricoxib can be decreased when combined with Mexiletine.
Midostaurin
The metabolism of Etoricoxib can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Etoricoxib can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Etoricoxib.
Mirabegron
The metabolism of Etoricoxib can be decreased when combined with Mirabegron.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Etoricoxib.
Mitotane
The serum concentration of Etoricoxib can be decreased when it is combined with Mitotane.
Moexipril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Etoricoxib.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.
Nadolol
Etoricoxib may decrease the antihypertensive activities of Nadolol.
Nadroparin
Etoricoxib may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Etoricoxib.
Nalidixic Acid
Etoricoxib may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Etoricoxib.
Nebivolol
Etoricoxib may decrease the antihypertensive activities of Nebivolol.
Nefazodone
The metabolism of Etoricoxib can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Etoricoxib can be decreased when combined with Nelfinavir.
Neomycin
Etoricoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Etoricoxib.
Netilmicin
Etoricoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant
The serum concentration of Etoricoxib can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Etoricoxib can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Etoricoxib can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Etoricoxib.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etoricoxib.
Nilotinib
The metabolism of Etoricoxib can be decreased when combined with Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Etoricoxib.
Norfloxacin
Etoricoxib may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Etoricoxib.
Olaparib
The metabolism of Etoricoxib can be decreased when combined with Olaparib.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Etoricoxib.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Etoricoxib is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Etoricoxib can be decreased when combined with Omeprazole.
Osimertinib
The serum concentration of Etoricoxib can be increased when it is combined with Osimertinib.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.
Oxprenolol
Etoricoxib may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etoricoxib.
Palbociclib
The serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.
Pamidronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.
Panobinostat
The serum concentration of Etoricoxib can be increased when it is combined with Panobinostat.
Paramethasone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Parecoxib.
Paromomycin
Etoricoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
The metabolism of Etoricoxib can be decreased when combined with Paroxetine.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Etoricoxib.
Pefloxacin
Etoricoxib may increase the neuroexcitatory activities of Pefloxacin.
Peginterferon Alfa-2b
The serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Etoricoxib may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Etoricoxib may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentobarbital
The metabolism of Etoricoxib can be increased when combined with Pentobarbital.
Pentosan Polysulfate
Etoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Etoricoxib.
Perindopril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Perindopril.
Phenindione
Etoricoxib may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Etoricoxib can be increased when combined with Phenobarbital.
Phenprocoumon
Etoricoxib may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etoricoxib.
Phenytoin
The metabolism of Etoricoxib can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.
Pindolol
Etoricoxib may decrease the antihypertensive activities of Pindolol.
Pirarubicin
Etoricoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Etoricoxib.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Etoricoxib.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Etoricoxib.
Plicamycin
Etoricoxib may decrease the excretion rate of Plicamycin which could result in a higher serum level.
Polyestradiol Phosphate
Etoricoxib may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Etoricoxib.
Posaconazole
The metabolism of Etoricoxib can be decreased when combined with Posaconazole.
Practolol
Etoricoxib may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Etoricoxib.
Prasterone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Prasterone.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Etoricoxib.
Prednicarbate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Pregnenolone.
Primidone
The metabolism of Etoricoxib can be increased when combined with Primidone.
Probenecid
The serum concentration of Etoricoxib can be increased when it is combined with Probenecid.
Promazine
The metabolism of Etoricoxib can be decreased when combined with Promazine.
Promestriene
Etoricoxib may increase the thrombogenic activities of Promestriene.
Propranolol
Etoricoxib may decrease the antihypertensive activities of Propranolol.
protein C, human
Etoricoxib may increase the anticoagulant activities of Protein C.
protein S, human
Etoricoxib may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Etoricoxib may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Etoricoxib can be decreased when combined with Pyrimethamine.
Quinapril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Quinapril.
Quinestrol
Etoricoxib may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Etoricoxib.
Quinidine
The metabolism of Etoricoxib can be decreased when combined with Quinidine.
Quinine
The metabolism of Etoricoxib can be decreased when combined with Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ramipril.
Ranolazine
The metabolism of Etoricoxib can be decreased when combined with Ranolazine.
Rescinnamine
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Etoricoxib.
Reviparin
Etoricoxib may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Etoricoxib may increase the anticoagulant activities of Reviparin.
Rifabutin
The metabolism of Etoricoxib can be increased when combined with Rifabutin.
Rifampin
The metabolism of Etoricoxib can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Etoricoxib can be increased when combined with Rifapentine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Etoricoxib.
Rimexolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.
Ritonavir
The metabolism of Etoricoxib can be decreased when combined with Ritonavir.
Rivaroxaban
Etoricoxib may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Etoricoxib.
Rolapitant
The metabolism of Etoricoxib can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Etoricoxib can be decreased when combined with Ropinirole.
Rosoxacin
Etoricoxib may increase the neuroexcitatory activities of Rosoxacin.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Etoricoxib.
Rucaparib
The metabolism of Etoricoxib can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Etoricoxib.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Etoricoxib.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Etoricoxib.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.
Saquinavir
The metabolism of Etoricoxib can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Etoricoxib can be decreased when combined with Saquinavir.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Etoricoxib.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Etoricoxib.
Secobarbital
The metabolism of Etoricoxib can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Etoricoxib.
Sertraline
Sertraline may increase the antiplatelet activities of Etoricoxib.
Sildenafil
The metabolism of Etoricoxib can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Etoricoxib can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Etoricoxib can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Etoricoxib.
Sisomicin
Etoricoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Etoricoxib.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Etoricoxib.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Etoricoxib.
Sorafenib
The metabolism of Etoricoxib can be decreased when combined with Sorafenib.
Sotalol
Etoricoxib may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Etoricoxib may increase the neuroexcitatory activities of Sparfloxacin.
Spectinomycin
Etoricoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.
Spirapril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Spirapril.
Spironolactone
Etoricoxib may decrease the antihypertensive activities of Spironolactone.
ST. JOHN'S WORT EXTRACT
The serum concentration of Etoricoxib can be decreased when it is combined with St. John's Wort.
Streptomycin
Etoricoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
Etoricoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.
Sulfadiazine
The metabolism of Etoricoxib can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Etoricoxib can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.
Sulfisoxazole
The metabolism of Etoricoxib can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Etoricoxib.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.
synthetic conjugated estrogens, A
Etoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Etoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Etoricoxib may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Etoricoxib.
Talinolol
Etoricoxib may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Etoricoxib.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium Tc-99m medronate.
Telaprevir
The metabolism of Etoricoxib can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Etoricoxib can be decreased when combined with Telithromycin.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.
Temafloxacin
Etoricoxib may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Etoricoxib.
Terbinafine
The metabolism of Etoricoxib can be decreased when combined with Terbinafine.
Teriflunomide
The serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.
Theophylline
The metabolism of Etoricoxib can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Etoricoxib can be decreased when combined with Theophylline.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Etoricoxib.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.
Tibolone
Etoricoxib may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Etoricoxib can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Etoricoxib can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Tiludronic acid.
Timolol
Etoricoxib may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Etoricoxib may decrease the antihypertensive activities of Timolol.
Tipranavir
The metabolism of Etoricoxib can be decreased when combined with Tipranavir.
Tixocortol
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Tixocortol.
Tobramycin
Etoricoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab
The serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Etoricoxib can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etoricoxib.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Etoricoxib.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Etoricoxib.
Trandolapril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Etoricoxib.
Tranylcypromine
The metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.
Triamcinolone
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Triamcinolone.
Triamterene
Etoricoxib may decrease the antihypertensive activities of Triamterene.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etoricoxib.
Trimethoprim
The metabolism of Etoricoxib can be decreased when combined with Trimethoprim.
Trovafloxacin
Etoricoxib may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Etoricoxib may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Etoricoxib.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Etoricoxib.
Valproate
The metabolism of Etoricoxib can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Etoricoxib can be decreased when combined with Valproic Acid.
Valrubicin
Etoricoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.
Valsartan
The metabolism of Etoricoxib can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Etoricoxib.
Vemurafenib
The serum concentration of Etoricoxib can be increased when it is combined with Vemurafenib.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Etoricoxib.
Verapamil
The metabolism of Etoricoxib can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Etoricoxib can be decreased when combined with Voriconazole.
Warfarin
Etoricoxib may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Etoricoxib can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Etoricoxib.
Ziprasidone
The metabolism of Etoricoxib can be decreased when combined with Ziprasidone.
Zofenopril
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Etoricoxib.
